Quarterly and annual results disclosed under 8-K Item 2.02.
Greenbrook TMS Inc. reported first quarter 2024 results: revenue $18.0 million, net income $14.5 million, EPS $(0.32) per share.
“the ransomware cyberattack on Change Healthcare Solutions LLC (“ Change Healthcare ”) that affected the broader healthcare industry, quarterly revenue decreased by only 7% to $18.0 million, down $1.3 million as compared to the first quarter of 2023 (“ Q1 2023 ”). · Regional operating loss increased by 401% in Q1 2024 to $2.5 million, up $2.0 million as compared to”
Vivos Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $3.4 million.
“Revenue was $3.4 million for the first quarter of 2024, compared to $3.8 million for the first quarter of 2023”
Rekor Systems, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 15, 2024, Rekor Systems, Inc. (the “Company”) issued a press release summarizing the Company’s financial results for the first quarter ended March 31, 2024.”
Spero Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $9.3 million, net income net loss of $12.7 million, or ($0.24) per share of common stock, basic and diluted, EPS ($0.24) per share.
“net loss of $13.3 million, or ($0.25) per share of common stock, basic and diluted, for the first quarter ended March 31, 2023. • Total revenue for the first quarter of 2024 was $9.3 million, compared with total revenue of $2.1 million for the first quarter of 2023. The revenue increase for the first quarter of 2024 was primarily due to an increase in collaboration”
Sadot Group Inc. reported first quarter ending March 31, 2024 results: revenue $107.9 million, net income $0.3 million.
“quarter ending March 31, 2024, Sadot Group reported an improvement in the Company’s net loss by approximately $0.8 million year over year. The Company had Q1 2024 revenues of $107.9 million, reporting a net loss of approximately $0.3 million, a considerable improvement compared to a net loss of approximately $1.1 million for the first quarter of 2023. Additionally,”
HYPERION DEFI, INC. reported the first quarter ended March 31, 2024 results: net income net loss was approximately $10.9 million, EPS $0.23 per share.
“For the first quarter of 2024, net loss was approximately $10.9 million, or $0.23 per share”
KULR Technology Group, Inc. reported the first quarter ended March 31, 2024 results: revenue $1.75 million, net income $5.01 million, EPS loss of $0.04 per share.
“First Quarter 2024 Financial Results Revenues: In the first quarter that ended March 31, 2024, revenue was flat at $1.75 million compared to $1.76 million reported in the same period last year. Contract Services revenue increased 769%, with revenue of approximately $1.13 million versus approximately $131 thousand in the same quarter last year. Cash and Accounts Receivable: As of March 31, 2024, the Company had cash and accounts receivable combined of $1.78 million. Gross Margins: Gross margin was 29% in the quarter ending March 31, 2024, compared to 37% in the same period last year. Selling, General and Administrative (SG&A) Expenses: SG&A expenses decreased to $4.21 million in the first quarter of 2024 from $5.10 million in the same period last year. The decrease in SG&A expenses was primarily due to decreases in outsourced services and stock-based compensation. Research and Development (R&D) Expenses: R&D expenses in the first quarter of 2024 decreased to $955 thousand from $1.81 mil”
Outlook Therapeutics, Inc. reported financial results for second quarter of fiscal year 2024.
“Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its second fiscal quarter ended March 31, 2024”
Ondas Inc. reported financial results for first quarter ended March 31, 2024.
“On May 15, 2024, Ondas Holdings Inc. (the "Company"), issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
AVENUE THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: net income $4.3 million, or $15.40 per share, EPS $15.40 per share.
“Net loss attributable to common stockholders for the first quarter of 2024 was $4.3 million, or $15.40 per share, compared to a net loss of $7.5 million, or $101.57 per share, for the first quarter of 2023.”
Insight Molecular Diagnostics Inc. reported the quarter ended March 31, 2024 results: revenue $176,000.
“Net revenue for the three months ended March 31, 2024 was $176,000, a decrease of 41% compared to the same period in 2023, due to decreased revenue from our Pharma Services business.”
Guardion Health Sciences, Inc. reported the three months ended March 31, 2024 results: revenue $2,999,645, net income $(4,746,744).
“the Special Meeting of its Stockholders to vote on these transactions. Financial highlights for the three months ended March 31, 2024 include the following: ● Total revenue was $2,999,645 for the three months ended March 31, 2024, as compared to $3,185,689 for the three months ended March 31, 2023, a decrease of $186,044 or 5.8%. Sales of the Viactiv ® product”
Aqua Metals, Inc. reported first quarter ended March 31, 2024 results: net income $5.8 million, EPS $(0.05) per basic and diluted share.
“The net loss for the first quarter of 2024 was $5.8 million, or $(0.05) per basic and diluted share, compared to a net loss of $4.6 million, or $(0.06) per basic and diluted share, for the first quarter of 2023.”
Medicine Man Technologies, Inc. reported first quarter ended March 31, 2024 results: revenue $41.6 million, net income $16.1 million.
“Total revenue in the first quarter of 2024 increased 4% to $41.6 million compared to $40.0 million for the same quarter last year.”
Polar Power, Inc. reported first quarter of 2024 results: revenue $1.8 million, net income $2.1 million, EPS $(0.12) per basic and diluted share.
“Q1 2024 Financial Highlights ● Net sales of $1.8 million compared to $4.2 million in the same period in 2023 ● Operating expenses of $1.6 million compared to $1.7 million in the same period in 2023 ● Net loss was $2.1 million, or $(0.12) per basic and diluted share, compared to a net loss of $1.1 million, or $(0.09) per basic and diluted share in the same period in 2023”
LeonaBio, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 15, 2024, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2024.”
Adaptimmune Therapeutics PLC reported first quarter ended March 31, 2024 results: revenue $5.7 million.
“Revenue for the three months ended March 31, 2024, was $5.7 million”
Evofem Biosciences, Inc. reported the three months ended March 31, 2024 results: revenue $3.6 million, net income loss from operations improved to $2.8 million.
“15.4 million beneficiaries. Effective July 1, 2024, Evofem will pay a 7.4% lower rebate to Medi-Cal on Phexxi prescriptions dispensed to its beneficiaries. ● Net sales were $3.6 million for the first quarter of 2024, reflecting anticipated cyclical softness following the wholesale acquisition cost (WAC) increase on January 1, 2024, and the impact of the”
Lifeward Ltd. reported the three months ended March 31, 2024 results: revenue $5.3 million, net income Net loss was $6.3 million, or $0.73 per share, EPS $0.73 per share. Guidance reaffirmed.
“MACs will enable us to further our mission of broader access to innovative exoskeleton technology for appropriate individuals.” First Quarter 2024 Financial Results Revenue was $5.3 million in the first quarter of 2024, compared to $1.2 million during the first quarter of 2023, up $4.1 million, or 340%. Revenue from the sale of products from the former ReWalk”
Cidara Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $8.5 million.
“Company’s multispecific CD73/PD-1 DFC, its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73. First Quarter 2024 Financial Results • Revenue totaled $8.5 million for the three months ended March 31, 2024, compared to $26.1 million for the same period in 2023. Revenue for the three months ended March 31, 2024 related to the achievement of”
AQUABOUNTY TECHNOLOGIES INC reported financial results for the first quarter ended March 31, 2024.
“On May 15, 2024, AquaBounty Technologies, Inc. issued a press release regarding its financial results and corporate updates for the quarter ended March 31, 2024.”
Celcuity Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $21.6 million, or $0.64 loss per share, EPS $0.64 loss per share.
“Celcuity Inc. (the “Company”) issued a press release regarding the Company’s financial results for the first quarter ended March 31, 2024.”
Elicio Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income $11.8 million, EPS $1.15.
“Net loss for the first quarter of 2024 was $11.8 million, compared to $8.0 million for the first quarter of 2023. Net loss per share for the first quarter of 2024 was $1.15 compared to $24.77 for the first quarter of 2023.”
BIORA THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: net income Net loss was $4.2 million, EPS net loss per share was $0.14.
“Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results”
Vislink Technologies, Inc. reported the first quarter ended March 31, 2024 results: revenue $8.6 million, net income $(0.9) million, or $(0.39) per share, EPS $(0.39) per share.
“date stated herein. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 Vislink Reports First Quarter 2024 Financial and Operational Results Total Revenue Increased 20% to $8.6 Million Driven by Surge in Sales to MilGov Customers New Product Sales and Enhanced Operating Efficiency Fuel Significant Profitability Improvements Mt. Olive, NJ — May 15, 2024 —”
Professional Diversity Network, Inc. reported the quarter ended March 31, 2024 results: revenue approximately $1,727,000, net income net loss from continuing operations of approximately $803,000, EPS ($0.07).
“Professional Diversity Network, Inc. Announces Financial Results for the Quarter Ended March 31, 2024”
authID Inc. reported the full fiscal year ending December 31, 2024 results: revenue $1.4 million to $1.6 million. Guidance initiated.
“Building on Q1 2024 revenue of $0.16 million, the Company estimates Total Revenue for the full fiscal year ending December 31, 2024 will be in the range of $1.4 million to $1.6 million.”
authID Inc. reported the three months ended March 31, 2024 results: revenue $0.16 million, net income $3.06 million, EPS $0.32.
“GAAP Metrics ● Total revenue for the three months ended March 31, 2024 increased over 300% to $0.16 million, compared with total revenue of $0.04 million for the three months ended March 31, 2023, principally due to the launch of several new customers that were signed in 2023. ● Operating expenses for the three months ended March 31, 2024 totaled $3.31 million, compared with $1.02 million for Q1 2023. The Q1 increase was driven by a one-time, non-cash expense reversal in Q1 2023 of $3.4 million from the reversal of certain stock-based compensation as a result of employee terminations, which was not repeated in 2024. From a consecutive quarter-over-quarter comparison, operating expenses for Q1 2024 remained in line with the operating expenses incurred in Q4 2023. ● Loss from Continuing Operations for the three months ended March 31, 2024 was $3.06 million, of which non-cash charges were $0.77 million, compared with a Loss of $1.78 million in Q1 2023. This was driven by a one-time event”
Ideal Power Inc. reported first quarter ended March 31, 2024 results: net income Net loss in the first quarter of 2024 was $2.5 million compared to $2.5 million in the first quarter of 2023..
“Commercial revenue increased to $78,739 in the first quarter of 2024 from $0 in the first quarter of 2023.”
Rezolute, Inc. reported the three months ended March 31, 2024 results: net income $17.1 million.
“Net loss was $17.1 million for the third quarter of fiscal 2024 compared with a net loss of $15.7 million for the same period a year ago.”
Avinger Inc reported first quarter ended March 31, 2024 results: revenue $1.9 million, net income $5.5 million.
“treatment of vascular disease, today reported results for the first quarter ended March 31, 2024. First Quarter and Recent Highlights ● Reported first quarter 2024 revenue of $1.9 million, and gross margin of 18% ● Continued full commercial launch of Tigereye ST, Avinger’s most advanced image-guided peripheral CTO-crossing device, and limited launch of the new”
DecisionPoint Systems, Inc. reported financial results for first quarter 2024.
“On May 15, 2024, DecisionPoint Systems, Inc. issued an earnings release for the quarter ended March 31, 2024.”
IZEA Worldwide, Inc. reported first quarter ended March 31, 2024 results: revenue $7.0 million, net income Net loss was $3.3 million.
“ZEA Reports Q1 2024 Revenue of $7.0 million ORLANDO, Fla (May 15, 2024) - IZEA Worldwide, Inc. (NASDAQ: IZEA ), the premier provider of influencer marketing technology, data, and services for the Creator Economy, reported its financial and operational results for the first quarter ended March 31, 2024.”
Lifeloc Technologies, Inc reported first quarter ended March 31, 2024 results: revenue $2.153 million, net income $(284) thousand, EPS $(0.12) per diluted share.
“Lifeloc posted quarterly net revenue of $2.153 million resulting in a quarterly net loss of $(284) thousand, or $(0.12) per diluted share.”
Sow Good Inc. reported the first quarter ended March 31, 2024 results: revenue $11.4 million, net income $510.6K.
“Revenue in the first quarter of 2024 increased significantly to $11.4 million”
BARFRESH FOOD GROUP INC. reported first quarter ended March 31, 2024 results: revenue $2.8 million, net income $449,000.
“Revenue for the first quarter of 2024 was $2.8 million, compared to $2.1 million in the first quarter of 2023.”
PDS Biotechnology Corp reported the three months ended March 31, 2024 results: net income approximately $10.6 million, EPS $0.30 per basic share and diluted share.
“Reported net loss was approximately $10.6 million, or $0.30 per basic share and diluted share, for the three months ended March 31, 2024”
Kodiak Sciences Inc. reported the quarter ended March 31, 2024 results: net income $43.0 million, or $0.82 per share on both a basic and diluted basis, EPS $0.82 per share on both a basic and diluted basis.
“Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024.”
Fluent, Inc. reported first quarter ended March 31, 2024 results: revenue Revenue of $66.0 million, net income Net loss of $6.3 million, EPS $0.45 per share.
“such filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 ex_633428.htm EXHIBIT 99.1 ex_633428.htm Exhibit 99.1 Fluent Announces First Quarter 2024 Financial Results • Revenue of $66.0 million for Q1 2024 • Net loss of $6.3 million for Q1 2024 • Gross profit (exclusive of depreciation and amortization) of $18.6 million for Q1 2024 • Media margin of $22.1 million for Q1”
BRC Group Holdings, Inc. reported three-month period ended March 31, 2024 results: revenue $343 million, net income Net loss available to common shareholders of $51 million, EPS $(1.71) per common share.
“31, 2024. First Quarter 2024 Summary ● Net loss available to common shareholders of $51 million primarily driven by non-cash, unrealized investment losses ● Total revenues of $343 million vs $432 million for the first quarter of 2023 ● Operating revenues (3) of $379 million vs $389 million ● Operating adjusted EBITDA (4)(5) of $66 million vs $88 million ● Total”
Xtant Medical Holdings, Inc. reported full year 2024 results: revenue $116 million to $120 million. Guidance raised.
“Xtant Medical raises its expectation for full year 2024 revenue to $116 million to $120 million, up from the Company’s prior guidance of $112 million to $116 million.”
Xtant Medical Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $27.9 million, net income $4.3 million, or $0.03 per share, EPS $0.03 per share. Guidance raised.
“treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights ● Revenue of $27.9 million, up 55%, compared to the prior year quarter ● Gross margin of 62.1%, up 340 basis points, compared to the prior year quarter ● Net loss of $4.4 million compared to $2.1 million”
Axe Compute Inc. reported the quarter ended March 31, 2024 results: revenue $419,646, net income net loss of approximately $4.2 million, EPS $(1.04).
“share for the quarter ended March 31, 2024, was $(1.04), compared to $(0.86) for the quarter ended March 31, 2023. Q1 2024 Financial Results: The company recorded revenue of $419,646 for the first quarter of 2024, compared to $239,895 for the comparable period in 2023. Revenues for the quarter ended March 31, 2024, and March 31, 2023, were primarily derived”
KINETA, INC./DE reported the three months ended March 31, 2024 results: revenue zero, net income $10.2 million, EPS $0.89.
“Net loss was $10.2 million, or $0.89 per basic and diluted share, for the three months ended March 31, 2024”
TREVENA INC reported the first quarter ended March 31, 2024 results: net income $7.7 million, EPS $0.36 per share.
“For the first quarter of 2024, the Company reported a net loss attributable to common stockholders of $7.7 million, or $0.36 per share, compared to $7.8 million, or $0.81 per share in the first quarter of 2023.”
Rein Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter, EPS The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarte.
“Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter in 2023. The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarter ended March 31, 2023.”
Fortress Biotech, Inc. reported financial results for first quarter ended March 31, 2024.
“Fortress Biotech, Inc. issued a press release to provide a corporate update and to announce its financial results for the three months ended March 31, 2024.”
Data Storage Corp reported the fiscal quarter ended March 31, 2024 results: revenue $8.2 million.
“new contracts with high profile clients, as well as streamlined operations for improved operations. As a result of our efforts, we witnessed a 20% increase in revenue to $8.2 million for the first quarter of 2024. Notably, our gross profit grew 42% with gross profit margin increasing to 36% for the first quarter of 2024 from 30% for the same period in”
INVO Fertility, Inc. reported financial results for the first quarter of 2024.
“On May 15, 2024, INVO Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the period ended March 31, 2024.”
DallasNews Corp reported financial results for the three months ended March 31, 2024.
“On May 15, 2024, DallasNews Corporation (the "Company") announced its consolidated financial results for the three months ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.